首页 > 最新文献

eGastroenterology最新文献

英文 中文
Endoscopic resection of large non-pedunculated colorectal polyps: current standards of treatment.
Pub Date : 2024-04-03 eCollection Date: 2024-04-01 DOI: 10.1136/egastro-2023-100025
Mahsa Taghiakbari, Dong Hyun Danny Kim, Roupen Djinbachian, Daniel von Renteln

Colorectal cancer is a significant public health concern, and large non-pedunculated colorectal polyps pose a substantial risk for malignancy and incomplete resection, which may lead to interval cancer. The choice of resection technique is influenced by various factors, including polyp size, morphology, location, submucosal invasion depth and endoscopist expertise. For non-cancerous superficial large non-pedunculated polyps, conventional hot or cold snare polypectomy, endoscopic mucosal resection and endoscopic submucosal dissection are common techniques for non-surgical therapeutic endoscopic resection of these polyps. This manuscript provides a comprehensive review of literature on current endoscopic resection techniques for large non-pedunculated colorectal polyps, emphasising indications, advantages, limitations and outcomes.

{"title":"Endoscopic resection of large non-pedunculated colorectal polyps: current standards of treatment.","authors":"Mahsa Taghiakbari, Dong Hyun Danny Kim, Roupen Djinbachian, Daniel von Renteln","doi":"10.1136/egastro-2023-100025","DOIUrl":"10.1136/egastro-2023-100025","url":null,"abstract":"<p><p>Colorectal cancer is a significant public health concern, and large non-pedunculated colorectal polyps pose a substantial risk for malignancy and incomplete resection, which may lead to interval cancer. The choice of resection technique is influenced by various factors, including polyp size, morphology, location, submucosal invasion depth and endoscopist expertise. For non-cancerous superficial large non-pedunculated polyps, conventional hot or cold snare polypectomy, endoscopic mucosal resection and endoscopic submucosal dissection are common techniques for non-surgical therapeutic endoscopic resection of these polyps. This manuscript provides a comprehensive review of literature on current endoscopic resection techniques for large non-pedunculated colorectal polyps, emphasising indications, advantages, limitations and outcomes.</p>","PeriodicalId":72879,"journal":{"name":"eGastroenterology","volume":"2 2","pages":"e100025"},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prebiotic selection influencing inflammatory bowel disease treatment outcomes: a review of the preclinical and clinical evidence 影响炎症性肠病治疗效果的益生元选择:临床前和临床证据综述
Pub Date : 2024-04-01 DOI: 10.1136/egastro-2023-100055
Amin Ariaee, Sabrina Koentgen, Hannah R. Wardill, Georgina L Hold, C. Prestidge, H. Armstrong, P. Joyce
Inflammatory bowel disease (IBD) is characterised by chronic inflammation in the gastrointestinal tract, with unclear aetiology but with known factors contributing to the disease, including genetics, immune responses, environmental factors and dysbiosis of the gut microbiota. Existing pharmacotherapies mainly target the inflammatory symptoms of disease, but recent research has highlighted the capacity for microbial-accessible carbohydrates that confer health benefits (ie, prebiotics) to selectively stimulate the growth of beneficial gut bacteria for improved IBD management. However, since prebiotics vary in source, chemical composition and microbiota effects, there is a clear need to understand the impact of prebiotic selection on IBD treatment outcomes. This review subsequently explores and contrasts the efficacy of prebiotics from various sources (β-fructans, galacto-oligosaccharides, xylo-oligosaccharides, resistant starch, pectin, β-glucans, glucomannans and arabinoxylans) in mitigating IBD symptomatology, when used as either standalone or adjuvant therapies. In preclinical animal colitis models, prebiotics have revealed type-dependent effects in positively modulating gut microbiota composition and subsequent attenuation of disease indicators and proinflammatory responses. While prebiotics have demonstrated therapeutic potential in animal models, clinical evidence for their precise efficacy remains limited, stressing the need for further investigation in human patients with IBD to facilitate their widespread clinical translation as microbiota-targeting IBD therapies.
炎症性肠病(IBD)以胃肠道慢性炎症为特征,病因不明,但已知的致病因素包括遗传、免疫反应、环境因素和肠道微生物群失调。现有的药物疗法主要针对疾病的炎症症状,但最近的研究强调,微生物可利用的碳水化合物(即益生素)可带来健康益处,选择性地刺激有益肠道细菌的生长,从而改善 IBD 的治疗效果。然而,由于益生元的来源、化学成分和微生物群效应各不相同,因此显然有必要了解益生元的选择对 IBD 治疗效果的影响。本综述随后探讨并对比了不同来源的益生元(β-果聚糖、半乳糖寡糖、木寡糖、抗性淀粉、果胶、β-葡聚糖、葡甘露聚糖和阿拉伯木聚糖)作为独立或辅助疗法在减轻 IBD 症状方面的功效。在临床前动物结肠炎模型中,益生元揭示了在积极调节肠道微生物群组成以及随后减轻疾病指标和促炎反应方面的类型依赖效应。虽然益生元已在动物模型中显示出治疗潜力,但有关其确切疗效的临床证据仍然有限,这强调了在人类 IBD 患者中开展进一步研究的必要性,以促进其作为微生物群靶向 IBD 疗法广泛应用于临床。
{"title":"Prebiotic selection influencing inflammatory bowel disease treatment outcomes: a review of the preclinical and clinical evidence","authors":"Amin Ariaee, Sabrina Koentgen, Hannah R. Wardill, Georgina L Hold, C. Prestidge, H. Armstrong, P. Joyce","doi":"10.1136/egastro-2023-100055","DOIUrl":"https://doi.org/10.1136/egastro-2023-100055","url":null,"abstract":"Inflammatory bowel disease (IBD) is characterised by chronic inflammation in the gastrointestinal tract, with unclear aetiology but with known factors contributing to the disease, including genetics, immune responses, environmental factors and dysbiosis of the gut microbiota. Existing pharmacotherapies mainly target the inflammatory symptoms of disease, but recent research has highlighted the capacity for microbial-accessible carbohydrates that confer health benefits (ie, prebiotics) to selectively stimulate the growth of beneficial gut bacteria for improved IBD management. However, since prebiotics vary in source, chemical composition and microbiota effects, there is a clear need to understand the impact of prebiotic selection on IBD treatment outcomes. This review subsequently explores and contrasts the efficacy of prebiotics from various sources (β-fructans, galacto-oligosaccharides, xylo-oligosaccharides, resistant starch, pectin, β-glucans, glucomannans and arabinoxylans) in mitigating IBD symptomatology, when used as either standalone or adjuvant therapies. In preclinical animal colitis models, prebiotics have revealed type-dependent effects in positively modulating gut microbiota composition and subsequent attenuation of disease indicators and proinflammatory responses. While prebiotics have demonstrated therapeutic potential in animal models, clinical evidence for their precise efficacy remains limited, stressing the need for further investigation in human patients with IBD to facilitate their widespread clinical translation as microbiota-targeting IBD therapies.","PeriodicalId":72879,"journal":{"name":"eGastroenterology","volume":"104 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140768597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PFDN6 contributes to colorectal cancer progression via transcriptional regulation PFDN6 通过转录调控促进结直肠癌进展
Pub Date : 2024-04-01 DOI: 10.1136/egastro-2023-100001
Fenghua Xu, Lingyang Kong, Xiao Sun, WenXiang Hui, Lan Jiang, Wenxin Han, ZhiFeng Xiao, Ning Li, DongFeng Chen, Nan Zheng, Jing Han, Lei Liu
Colorectal cancer (CRC) is a common cancer worldwide. Although there are several treatments for cancer, the therapeutic effect on CRC remains unsatisfactory, and it is imperative to identify new therapeutic targets.Prefoldin (PFDN) is mainly used in the cytoskeleton assembly during the folding of actin and tubulin monomers. However, whether PFDN subunits are involved in regulating the development of CRC remains to be elucidated. In this study, molecular biology, cell culture, transcriptome sequencing and other experimental techniques, combined with bioinformatics, were used to verify the regulatory effects of PFDN6 on CRC.PFDN6 expression is elevated in patients with CRC and is closely associated with the development of CRC. Knockdown of PFDN6 reduced the tumour cell number, promoted apoptosis, and inhibited the migration and invasion of CRC cells in HCT-116 and RKO cell lines. Mechanistically, differentially expressed genes and related signalling pathways in RKO cells after PFDN6 knockdown were analysed by transcriptome sequencing.PFDN6 was found to regulate the generation and development of CRC by targeting ZNF575. These results open new avenues for therapeutic interventions for patients with CRC.
结直肠癌(CRC)是全球常见的癌症。尽管目前有多种治疗癌症的方法,但对 CRC 的治疗效果仍不理想,因此寻找新的治疗靶点势在必行。预折叠蛋白(PFDN)主要用于细胞骨架组装过程中肌动蛋白和微管蛋白单体的折叠。然而,PFDN亚基是否参与调控CRC的发展仍有待阐明。本研究采用分子生物学、细胞培养、转录组测序等实验技术,并结合生物信息学,验证了PFDN6对CRC的调控作用。在HCT-116和RKO细胞系中,敲除PFDN6可减少肿瘤细胞数量,促进细胞凋亡,抑制CRC细胞的迁移和侵袭。通过转录组测序分析了PFDN6敲除后RKO细胞中不同表达基因及相关信号通路的机制。这些结果为CRC患者的治疗干预开辟了新途径。
{"title":"PFDN6 contributes to colorectal cancer progression via transcriptional regulation","authors":"Fenghua Xu, Lingyang Kong, Xiao Sun, WenXiang Hui, Lan Jiang, Wenxin Han, ZhiFeng Xiao, Ning Li, DongFeng Chen, Nan Zheng, Jing Han, Lei Liu","doi":"10.1136/egastro-2023-100001","DOIUrl":"https://doi.org/10.1136/egastro-2023-100001","url":null,"abstract":"Colorectal cancer (CRC) is a common cancer worldwide. Although there are several treatments for cancer, the therapeutic effect on CRC remains unsatisfactory, and it is imperative to identify new therapeutic targets.Prefoldin (PFDN) is mainly used in the cytoskeleton assembly during the folding of actin and tubulin monomers. However, whether PFDN subunits are involved in regulating the development of CRC remains to be elucidated. In this study, molecular biology, cell culture, transcriptome sequencing and other experimental techniques, combined with bioinformatics, were used to verify the regulatory effects of PFDN6 on CRC.PFDN6 expression is elevated in patients with CRC and is closely associated with the development of CRC. Knockdown of PFDN6 reduced the tumour cell number, promoted apoptosis, and inhibited the migration and invasion of CRC cells in HCT-116 and RKO cell lines. Mechanistically, differentially expressed genes and related signalling pathways in RKO cells after PFDN6 knockdown were analysed by transcriptome sequencing.PFDN6 was found to regulate the generation and development of CRC by targeting ZNF575. These results open new avenues for therapeutic interventions for patients with CRC.","PeriodicalId":72879,"journal":{"name":"eGastroenterology","volume":"20 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140791923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bile acids regulation of cellular stress responses in liver physiology and diseases. 胆汁酸对肝脏生理和疾病中细胞应激反应的调节。
Pub Date : 2024-04-01 Epub Date: 2024-05-31 DOI: 10.1136/egastro-2024-100074
Tiangang Li, Mohammad Nazmul Hasan, Lijie Gu

Bile acids are physiological detergents and signalling molecules that are critically implicated in liver health and diseases. Dysregulation of bile acid homeostasis alters cell function and causes cell injury in chronic liver diseases. Therapeutic agents targeting bile acid synthesis, transport and signalling hold great potential for treatment of chronic liver diseases. The broad cellular and physiological impacts of pharmacological manipulations of bile acid metabolism are still incompletely understood. Recent research has discovered new links of bile acid signalling to the regulation of autophagy and lysosome biology, redox homeostasis and endoplasmic reticulum stress. These are well-conserved mechanisms that allow cells to adapt to nutrient and organelle stresses and play critical roles in maintaining cellular integrity and promoting survival. However, dysregulation of these cellular pathways is often observed in chronic liver diseases, which exacerbates cellular dysfunction to contribute to disease pathogenesis. Therefore, identification of these novel links has significantly advanced our knowledge of bile acid biology and physiology, which is needed to understand the contributions of bile acid dysregulation in disease pathogenesis, establish bile acids as diagnostic markers and develop bile acid-based pharmacological interventions. In this review, we will first discuss the roles of bile acid dysregulation in the pathogenesis of chronic liver diseases, and then discuss the recent findings on the crosstalk of bile acid signalling and cellular stress responses. Future investigations are needed to better define the roles of these crosstalks in regulating cellular function and disease processes.

胆汁酸是生理洗涤剂和信号分子,与肝脏的健康和疾病密切相关。胆汁酸平衡失调会改变细胞功能,并导致慢性肝病中的细胞损伤。针对胆汁酸合成、转运和信号传导的治疗药物在治疗慢性肝病方面具有巨大潜力。对胆汁酸代谢的药理作用对细胞和生理的广泛影响仍未完全了解。最近的研究发现了胆汁酸信号与自噬和溶酶体生物学、氧化还原稳态和内质网应激调控之间的新联系。这些机制保存完好,可使细胞适应营养和细胞器压力,并在维持细胞完整性和促进存活方面发挥关键作用。然而,在慢性肝病中经常可以观察到这些细胞通路的失调,这加剧了细胞功能障碍,从而导致疾病的发病。因此,发现这些新的联系极大地促进了我们对胆汁酸生物学和生理学的了解,而了解胆汁酸失调在疾病发病机制中的作用、将胆汁酸确立为诊断标志物以及开发基于胆汁酸的药物干预措施都需要胆汁酸。在这篇综述中,我们将首先讨论胆汁酸失调在慢性肝病发病机制中的作用,然后讨论胆汁酸信号传导与细胞应激反应相互影响的最新发现。未来的研究需要更好地界定这些串联在调节细胞功能和疾病过程中的作用。
{"title":"Bile acids regulation of cellular stress responses in liver physiology and diseases.","authors":"Tiangang Li, Mohammad Nazmul Hasan, Lijie Gu","doi":"10.1136/egastro-2024-100074","DOIUrl":"10.1136/egastro-2024-100074","url":null,"abstract":"<p><p>Bile acids are physiological detergents and signalling molecules that are critically implicated in liver health and diseases. Dysregulation of bile acid homeostasis alters cell function and causes cell injury in chronic liver diseases. Therapeutic agents targeting bile acid synthesis, transport and signalling hold great potential for treatment of chronic liver diseases. The broad cellular and physiological impacts of pharmacological manipulations of bile acid metabolism are still incompletely understood. Recent research has discovered new links of bile acid signalling to the regulation of autophagy and lysosome biology, redox homeostasis and endoplasmic reticulum stress. These are well-conserved mechanisms that allow cells to adapt to nutrient and organelle stresses and play critical roles in maintaining cellular integrity and promoting survival. However, dysregulation of these cellular pathways is often observed in chronic liver diseases, which exacerbates cellular dysfunction to contribute to disease pathogenesis. Therefore, identification of these novel links has significantly advanced our knowledge of bile acid biology and physiology, which is needed to understand the contributions of bile acid dysregulation in disease pathogenesis, establish bile acids as diagnostic markers and develop bile acid-based pharmacological interventions. In this review, we will first discuss the roles of bile acid dysregulation in the pathogenesis of chronic liver diseases, and then discuss the recent findings on the crosstalk of bile acid signalling and cellular stress responses. Future investigations are needed to better define the roles of these crosstalks in regulating cellular function and disease processes.</p>","PeriodicalId":72879,"journal":{"name":"eGastroenterology","volume":"2 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11257078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141725196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incorporating biological and clinical insights into variant choice for Mendelian randomisation: examples and principles 将生物学和临床见解纳入孟德尔随机化的变体选择:实例和原则
Pub Date : 2024-01-01 DOI: 10.1136/egastro-2023-100042
S. Burgess, H. T. Cronjé
Mendelian randomisation is an accessible and valuable epidemiological approach to provide insight into the causal nature of relationships between risk factor exposures and disease outcomes. However, if performed without critical thought, we may simply have replaced one set of implausible assumptions (no unmeasured confounding or reverse causation) with another set of implausible assumptions (no pleiotropy or other instrument invalidity). The most critical decision to avoid pleiotropy is which genetic variants to use as instrumental variables. Two broad strategies for instrument selection are a biologically motivated strategy and a genome-wide strategy; in general, a biologically motivated strategy is preferred. In this review, we discuss various ways of implementing a biologically motivated selection strategy: using variants in a coding gene region for the exposure or a gene region that encodes a regulator of exposure levels, using a positive control variable and using a biomarker as the exposure rather than its behavioural proxy. In some cases, a genome-wide analysis can provide important complementary evidence, even when its reliability is questionable. In other cases, a biologically-motivated analysis may not be possible. The choice of genetic variants must be informed by biological and functional considerations where possible, requiring collaboration to combine biological and clinical insights with appropriate statistical methodology.
孟德尔随机法是一种简便易行且极具价值的流行病学方法,可帮助我们深入了解风险因素暴露与疾病结果之间的因果关系。然而,如果不加批判性思考,我们可能只是用另一组难以置信的假设(无褶效或其他工具无效)取代了一组难以置信的假设(无未测量混杂或反向因果关系)。避免多效性的最关键决定因素是使用哪些遗传变异作为工具变量。工具选择的两大策略分别是生物动机策略和全基因组策略;一般来说,生物动机策略更受青睐。在这篇综述中,我们将讨论实施生物动机选择策略的各种方法:使用暴露的编码基因区变异或编码暴露水平调节因子的基因区变异、使用阳性对照变量和使用生物标志物作为暴露而不是其行为替代物。在某些情况下,全基因组分析可以提供重要的补充证据,即使其可靠性值得怀疑。在另一些情况下,可能无法进行生物学分析。基因变异的选择必须尽可能考虑生物学和功能学因素,这就需要合作,将生物学和临床见解与适当的统计方法结合起来。
{"title":"Incorporating biological and clinical insights into variant choice for Mendelian randomisation: examples and principles","authors":"S. Burgess, H. T. Cronjé","doi":"10.1136/egastro-2023-100042","DOIUrl":"https://doi.org/10.1136/egastro-2023-100042","url":null,"abstract":"Mendelian randomisation is an accessible and valuable epidemiological approach to provide insight into the causal nature of relationships between risk factor exposures and disease outcomes. However, if performed without critical thought, we may simply have replaced one set of implausible assumptions (no unmeasured confounding or reverse causation) with another set of implausible assumptions (no pleiotropy or other instrument invalidity). The most critical decision to avoid pleiotropy is which genetic variants to use as instrumental variables. Two broad strategies for instrument selection are a biologically motivated strategy and a genome-wide strategy; in general, a biologically motivated strategy is preferred. In this review, we discuss various ways of implementing a biologically motivated selection strategy: using variants in a coding gene region for the exposure or a gene region that encodes a regulator of exposure levels, using a positive control variable and using a biomarker as the exposure rather than its behavioural proxy. In some cases, a genome-wide analysis can provide important complementary evidence, even when its reliability is questionable. In other cases, a biologically-motivated analysis may not be possible. The choice of genetic variants must be informed by biological and functional considerations where possible, requiring collaboration to combine biological and clinical insights with appropriate statistical methodology.","PeriodicalId":72879,"journal":{"name":"eGastroenterology","volume":"103 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139638552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions 预测炎症性肠病反应的发病机制和精准医疗:进展与未来方向
Pub Date : 2024-01-01 DOI: 10.1136/egastro-2023-100006
R. Little, Thisun Jayawardana, Sabrina Koentgen, Fan Zhang, Susan J Connor, Alex Boussioutas, M. Ward, Peter R. Gibson, Miles P Sparrow, Georgina L Hold
The pathogenesis of inflammatory bowel disease (IBD) is complex and multifactorial. Undertreated disease has substantial individual and societal consequences. Current patient classification and subsequent positioning of IBD therapy are based on crude, readily accessible clinical data. These broad parameters are unlikely to reflect underlying molecular profiles and may account for the observed heterogeneity in treatment response. Precision medicine offers identification and integration of molecular profiles into clinical decision-making. Despite several promising scientific and technological advances, the pathogenesis and targetable molecular drivers of IBD remain incompletely understood. Precision medicine therefore remains aspirational. This comprehensive narrative review describes our current understanding of IBD pathophysiology, highlights preliminary genetic, immunological and microbial predictors of treatment response and outlines the role of ‘big data’ and machine learning in the path towards precision medicine.
炎症性肠病(IBD)的发病机制复杂且多因素。治疗不当会对个人和社会造成严重后果。目前的患者分类和随后的 IBD 治疗定位都是基于粗略的、容易获得的临床数据。这些宽泛的参数不太可能反映潜在的分子特征,也可能是导致治疗反应异质性的原因。精准医疗可识别分子特征并将其纳入临床决策。尽管在科学和技术方面取得了一些有希望的进展,但人们对 IBD 的发病机制和可靶向的分子驱动因素仍不完全了解。因此,精准医学仍是一个憧憬。本综述描述了我们目前对 IBD 病理生理学的理解,强调了治疗反应的初步遗传学、免疫学和微生物学预测因素,并概述了 "大数据 "和机器学习在实现精准医学道路上的作用。
{"title":"Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions","authors":"R. Little, Thisun Jayawardana, Sabrina Koentgen, Fan Zhang, Susan J Connor, Alex Boussioutas, M. Ward, Peter R. Gibson, Miles P Sparrow, Georgina L Hold","doi":"10.1136/egastro-2023-100006","DOIUrl":"https://doi.org/10.1136/egastro-2023-100006","url":null,"abstract":"The pathogenesis of inflammatory bowel disease (IBD) is complex and multifactorial. Undertreated disease has substantial individual and societal consequences. Current patient classification and subsequent positioning of IBD therapy are based on crude, readily accessible clinical data. These broad parameters are unlikely to reflect underlying molecular profiles and may account for the observed heterogeneity in treatment response. Precision medicine offers identification and integration of molecular profiles into clinical decision-making. Despite several promising scientific and technological advances, the pathogenesis and targetable molecular drivers of IBD remain incompletely understood. Precision medicine therefore remains aspirational. This comprehensive narrative review describes our current understanding of IBD pathophysiology, highlights preliminary genetic, immunological and microbial predictors of treatment response and outlines the role of ‘big data’ and machine learning in the path towards precision medicine.","PeriodicalId":72879,"journal":{"name":"eGastroenterology","volume":"23 21","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139631601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and prediction of hepatocellular carcinoma in alcohol-associated liver disease: a retrospective study of 136 571 patients with chronic liver diseases 酒精相关性肝病中肝细胞癌的发病率和预测:对 136 571 名慢性肝病患者的回顾性研究
Pub Date : 2024-01-01 DOI: 10.1136/egastro-2023-100036
B. Chang, Hui Tian, Ang Huang, Xingran Zhai, Qiaoling Wang, Lin Han, Xueyuan Jin, Li Gao, Qing-xiang Liang, Baosen Li, Yinying Lu, Huan Xie, Dong Ji, Zhengsheng Zou
To explore the incidence of alcohol-related hepatocellular carcinoma (HCC), evaluate possible synergisms between alcohol and well-known risk factors associated with HCC and establish a nomogram to predict alcohol-associated liver disease (ALD)-related HCC risk.A database of 136 571 inpatients in the Fifth Medical Center of Chinese PLA General Hospital from 2002 to 2018 with chronic liver disease was established. Data were collected by medical records review. Multivariate logistic regression was used to identify the independent high-risk factors associated with HCC, and then were incorporated into a novel nomogram. Afterward, the new established model was validated using external cohort by receiver operating characteristic curves analysis. For external cohort, 1646 patients with ALD admitted to our hospital from 2019 to 2021 were included. ALD was diagnosed on the basis of a history of sustained heavy alcohol intake greater than 40 g/day for men and 20 g/day for women for >5 years, clinical evidence of liver disease and supporting laboratory abnormalities.Over the last 17 years, trends showed obviously increases in ALD. ALD-related HCC experienced a significant increase from 5.8% to 30.7%, whereas hepatitis B virus (HBV)-related HCC declined from 77.6% to 52.0%. In patients with ALD-related HCC (5119), 3816 (74.54%) cases had HBV infection, 493 (9.63%) cases had hepatitis C virus (HCV) infection, 71 (1.39%) cases were coinfected with both HBV and HCV, and 739 (14.44%) cases had neither HBV nor HCV infection. Drinking years (OR 1.009, 95% CI (1.000 to 1.017)), age (OR 1.060, 95% CI (1.051 to 1.069)), diabetes mellitus (OR 1.314, 95% CI (1.123 to 1.538)), HBV infection (OR 4.905, 95% CI (4.242 to 5.671)), liver cirrhosis (OR 4.922, 95% CI (3.887 to 6.232)) and male sex (OR 17.011, 95%CI (2.296 to 126.013)) were associated with increased risk of HCC in patients with ALD. A nomogram had a concordance index of 0.786 (95% CI 0.773 to 0.799) and had well-fitted calibration curves. These results were successfully validated both in the internal cohort and external cohort.The prevalence of ALD and ALD-related HCC has been increased dramatically. The nomogram model established here with its high accuracy and easy-to-use features achieved an optimal prediction of HCC development in patients with ALD, which can help clinicians to develop an individualised and precise treatment strategy.
目的:探讨酒精相关肝细胞癌(HCC)的发病率,评估酒精与众所周知的HCC相关风险因素之间可能存在的协同作用,并建立预测酒精相关肝病(ALD)相关HCC风险的提名图。通过病历回顾收集数据。采用多元逻辑回归确定与 HCC 相关的独立高危因素,并将其纳入新的提名图。随后,通过接收者操作特征曲线分析,利用外部队列对新建立的模型进行了验证。在外部队列中,纳入了我院在2019年至2021年期间收治的1646名ALD患者。ALD的诊断依据是男性持续大量摄入酒精超过40克/天,女性持续大量摄入酒精超过20克/天,且持续时间超过5年,有肝脏疾病的临床证据和支持性实验室异常。在过去的 17 年中,ALD 的发病率呈明显上升趋势,与 ALD 相关的 HCC 从 5.8% 显著上升至 30.7%,而与乙型肝炎病毒(HBV)相关的 HCC 则从 77.6% 下降至 52.0%。在与 ALD 相关的 HCC 患者(5119 例)中,有 3816 例(74.54%)感染了 HBV,493 例(9.63%)感染了丙型肝炎病毒(HCV),71 例(1.39%)同时感染了 HBV 和 HCV,739 例(14.44%)既未感染 HBV 也未感染 HCV。饮酒年限(OR 1.009,95% CI(1.000 至 1.017))、年龄(OR 1.060,95% CI(1.051 至 1.069))、糖尿病(OR 1.314,95% CI(1.123 至 1.538))、HBV 感染(OR 4.905,95% CI(4.肝硬化(OR 4.922,95% CI (3.887 to 6.232))和男性(OR 17.011,95%CI (2.296 to 126.013))与 ALD 患者罹患 HCC 的风险增加有关。提名图的一致性指数为 0.786(95% CI 0.773 至 0.799),校准曲线拟合良好。这些结果在内部队列和外部队列中都得到了成功验证。本研究建立的提名图模型具有准确度高、易于使用等特点,可对ALD患者的HCC发展情况进行最佳预测,从而帮助临床医生制定个体化的精准治疗策略。
{"title":"Prevalence and prediction of hepatocellular carcinoma in alcohol-associated liver disease: a retrospective study of 136 571 patients with chronic liver diseases","authors":"B. Chang, Hui Tian, Ang Huang, Xingran Zhai, Qiaoling Wang, Lin Han, Xueyuan Jin, Li Gao, Qing-xiang Liang, Baosen Li, Yinying Lu, Huan Xie, Dong Ji, Zhengsheng Zou","doi":"10.1136/egastro-2023-100036","DOIUrl":"https://doi.org/10.1136/egastro-2023-100036","url":null,"abstract":"To explore the incidence of alcohol-related hepatocellular carcinoma (HCC), evaluate possible synergisms between alcohol and well-known risk factors associated with HCC and establish a nomogram to predict alcohol-associated liver disease (ALD)-related HCC risk.A database of 136 571 inpatients in the Fifth Medical Center of Chinese PLA General Hospital from 2002 to 2018 with chronic liver disease was established. Data were collected by medical records review. Multivariate logistic regression was used to identify the independent high-risk factors associated with HCC, and then were incorporated into a novel nomogram. Afterward, the new established model was validated using external cohort by receiver operating characteristic curves analysis. For external cohort, 1646 patients with ALD admitted to our hospital from 2019 to 2021 were included. ALD was diagnosed on the basis of a history of sustained heavy alcohol intake greater than 40 g/day for men and 20 g/day for women for >5 years, clinical evidence of liver disease and supporting laboratory abnormalities.Over the last 17 years, trends showed obviously increases in ALD. ALD-related HCC experienced a significant increase from 5.8% to 30.7%, whereas hepatitis B virus (HBV)-related HCC declined from 77.6% to 52.0%. In patients with ALD-related HCC (5119), 3816 (74.54%) cases had HBV infection, 493 (9.63%) cases had hepatitis C virus (HCV) infection, 71 (1.39%) cases were coinfected with both HBV and HCV, and 739 (14.44%) cases had neither HBV nor HCV infection. Drinking years (OR 1.009, 95% CI (1.000 to 1.017)), age (OR 1.060, 95% CI (1.051 to 1.069)), diabetes mellitus (OR 1.314, 95% CI (1.123 to 1.538)), HBV infection (OR 4.905, 95% CI (4.242 to 5.671)), liver cirrhosis (OR 4.922, 95% CI (3.887 to 6.232)) and male sex (OR 17.011, 95%CI (2.296 to 126.013)) were associated with increased risk of HCC in patients with ALD. A nomogram had a concordance index of 0.786 (95% CI 0.773 to 0.799) and had well-fitted calibration curves. These results were successfully validated both in the internal cohort and external cohort.The prevalence of ALD and ALD-related HCC has been increased dramatically. The nomogram model established here with its high accuracy and easy-to-use features achieved an optimal prediction of HCC development in patients with ALD, which can help clinicians to develop an individualised and precise treatment strategy.","PeriodicalId":72879,"journal":{"name":"eGastroenterology","volume":"262 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139636209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CLivD score modifies FIB-4 performance in liver fibrosis detection in the US general population CLivD评分改变了FIB-4在美国普通人群肝纤维化检测中的表现
Pub Date : 2023-12-01 DOI: 10.1136/egastro-2023-100035
F. Åberg, Mitja Lääperi, V. Männistö
Steatotic liver disease (SLD) is a growing global concern. The Chronic Liver Disease (CLivD) risk score predicts liver-related outcomes in the general population using easily accessible variables with or without laboratory tests (CLivDlaband CLivDnon-lab). We assessed CLivD’s associations with liver steatosis, fibrosis and its combined performance with fibrosis-4 (FIB-4) for advanced fibrosis detection.Using the National Health and Nutrition Examination Survey data (2017–2020), 3603 participants aged 40–70 years with valid liver stiffness measurements (LSMs) were included. Advanced fibrosis was defined as LSM ≥12 kPa, and SLD as controlled attenuation parameter ≥288 dB/m.Significant associations were found between CLivD and SLD and advanced fibrosis. CLivDlabhad an area under the curve (AUC) for advanced fibrosis of 0.72 (95% CI 0.68 to 0.77), while CLivDnon-labhad an AUC of 0.68 (95% CI 0.64 to 0.72), both slightly higher than FIB-4 (AUC 0.66, 95% CI 0.60 to 0.72). Among participants without obesity, AUC of CLivDlabwas 0.82 (95% CI 0.76 to 0.88) and AUC of CLivDnon-labwas 0.72 (95% CI 0.65 to 0.79). The CLivD score improved FIB-4’s AUC for advanced fibrosis detection from <0.5 at minimal CLivD scores to >0.8 at high CLivD scores. A sequential CLivD→FIB-4 strategy outperformed universal FIB-4 testing, enhancing specificity from 72% to 83%, with sensitivity at 51%–53%. This strategy identified a subgroup with a 55% prevalence of advanced fibrosis, while 47% had minimal-risk CLivD scores, eliminating the need for FIB-4 testing.The CLivD score, designed for predicting liver-related outcomes, effectively identifies liver steatosis and advanced fibrosis in the general population. Combining CLivD with FIB-4 enhances advanced fibrosis detection accuracy. The CLivD score could enhance population-based liver fibrosis screening, optimising resource allocation.
脂肪肝(SLD)是全球日益关注的问题。慢性肝病(CLivD)风险评分利用易于获取的变量,通过或不通过实验室检测(CLivDlab 和 CLivDnon-lab)预测普通人群中与肝脏相关的结果。我们评估了CLivD与肝脏脂肪变性、肝纤维化的关联,以及其与纤维化-4(FIB-4)联合检测晚期肝纤维化的性能。利用美国国家健康与营养调查数据(2017-2020年),纳入了3603名年龄在40-70岁之间、具有有效肝脏硬度测量值(LSM)的参与者。晚期肝纤维化的定义为 LSM ≥12 kPa,SLD 为受控衰减参数 ≥288 dB/m.研究发现 CLivD 和 SLD 与晚期肝纤维化之间存在显著关联。CLivDlab的晚期纤维化曲线下面积(AUC)为0.72(95% CI 0.68至0.77),而CLivDnon-lab的AUC为0.68(95% CI 0.64至0.72),均略高于FIB-4(AUC 0.66,95% CI 0.60至0.72)。在无肥胖症的参与者中,CLivDlab的AUC为0.82(95% CI 0.76至0.88),CLivDnon-lab的AUC为0.72(95% CI 0.65至0.79)。CLivD评分提高了FIB-4的晚期纤维化检测AUC,CLivD高分时AUC为0.8。CLivD→FIB-4连续检测策略优于FIB-4全面检测,特异性从72%提高到83%,灵敏度为51%-53%。CLivD评分是为预测肝脏相关结果而设计的,能有效识别普通人群中的肝脏脂肪变性和晚期纤维化。将CLivD与FIB-4结合可提高晚期肝纤维化检测的准确性。CLivD评分可加强基于人群的肝纤维化筛查,优化资源分配。
{"title":"CLivD score modifies FIB-4 performance in liver fibrosis detection in the US general population","authors":"F. Åberg, Mitja Lääperi, V. Männistö","doi":"10.1136/egastro-2023-100035","DOIUrl":"https://doi.org/10.1136/egastro-2023-100035","url":null,"abstract":"Steatotic liver disease (SLD) is a growing global concern. The Chronic Liver Disease (CLivD) risk score predicts liver-related outcomes in the general population using easily accessible variables with or without laboratory tests (CLivDlaband CLivDnon-lab). We assessed CLivD’s associations with liver steatosis, fibrosis and its combined performance with fibrosis-4 (FIB-4) for advanced fibrosis detection.Using the National Health and Nutrition Examination Survey data (2017–2020), 3603 participants aged 40–70 years with valid liver stiffness measurements (LSMs) were included. Advanced fibrosis was defined as LSM ≥12 kPa, and SLD as controlled attenuation parameter ≥288 dB/m.Significant associations were found between CLivD and SLD and advanced fibrosis. CLivDlabhad an area under the curve (AUC) for advanced fibrosis of 0.72 (95% CI 0.68 to 0.77), while CLivDnon-labhad an AUC of 0.68 (95% CI 0.64 to 0.72), both slightly higher than FIB-4 (AUC 0.66, 95% CI 0.60 to 0.72). Among participants without obesity, AUC of CLivDlabwas 0.82 (95% CI 0.76 to 0.88) and AUC of CLivDnon-labwas 0.72 (95% CI 0.65 to 0.79). The CLivD score improved FIB-4’s AUC for advanced fibrosis detection from <0.5 at minimal CLivD scores to >0.8 at high CLivD scores. A sequential CLivD→FIB-4 strategy outperformed universal FIB-4 testing, enhancing specificity from 72% to 83%, with sensitivity at 51%–53%. This strategy identified a subgroup with a 55% prevalence of advanced fibrosis, while 47% had minimal-risk CLivD scores, eliminating the need for FIB-4 testing.The CLivD score, designed for predicting liver-related outcomes, effectively identifies liver steatosis and advanced fibrosis in the general population. Combining CLivD with FIB-4 enhances advanced fibrosis detection accuracy. The CLivD score could enhance population-based liver fibrosis screening, optimising resource allocation.","PeriodicalId":72879,"journal":{"name":"eGastroenterology","volume":"333 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139016090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pioneering use of genetic analysis forCDH1to identify candidates for prophylactic total gastrectomy to prevent hereditary diffuse gastric cancer 率先使用 CDH1 基因分析确定预防性全胃切除术的候选者,以预防遗传性弥漫性胃癌的发生
Pub Date : 2023-12-01 DOI: 10.1136/egastro-2023-100017
F. Mokhtari-Esbuie, Bryan C Szeglin, Mohsen Rouhani Ravari, Mark Duncan, John W Harmon
Worldwide, gastric cancer results in significant morbidity and mortality. Ten per cent of patients with gastric cancer have a strong family history of the disease.CDH1(E-cadherin) has been identified as a key gene whose mutation leads to hereditary diffuse gastric cancer. We overviewed 33 articles with prophylactic total gastrectomy and assessed the outcomes and benefits. Families with mutations inCDH1may benefit from early prophylactic total gastrectomy. Dr Mark Duncan has applied his experience as a high-volume gastric cancer surgeon to treat not only individual patients, but several generations of patients within a family. This use of prophylactic total gastrectomy is well tolerated by patients and prevents the future development of gastric cancer.
在世界范围内,胃癌的发病率和死亡率都很高。10%的胃癌患者有强烈的胃癌家族史,cdh1 (e -钙粘蛋白)已被确定为一个关键基因,其突变导致遗传性弥漫性胃癌。我们回顾了33篇关于预防性全胃切除术的文章,并评估了结果和益处。有incdh1突变的家庭可能从早期预防性全胃切除术中获益。马克·邓肯医生运用他作为胃癌外科医生的经验,不仅治疗单个病人,而且治疗一个家庭中几代人的病人。这种预防性全胃切除术的使用被患者很好地耐受,并防止胃癌的未来发展。
{"title":"Pioneering use of genetic analysis forCDH1to identify candidates for prophylactic total gastrectomy to prevent hereditary diffuse gastric cancer","authors":"F. Mokhtari-Esbuie, Bryan C Szeglin, Mohsen Rouhani Ravari, Mark Duncan, John W Harmon","doi":"10.1136/egastro-2023-100017","DOIUrl":"https://doi.org/10.1136/egastro-2023-100017","url":null,"abstract":"Worldwide, gastric cancer results in significant morbidity and mortality. Ten per cent of patients with gastric cancer have a strong family history of the disease.CDH1(E-cadherin) has been identified as a key gene whose mutation leads to hereditary diffuse gastric cancer. We overviewed 33 articles with prophylactic total gastrectomy and assessed the outcomes and benefits. Families with mutations inCDH1may benefit from early prophylactic total gastrectomy. Dr Mark Duncan has applied his experience as a high-volume gastric cancer surgeon to treat not only individual patients, but several generations of patients within a family. This use of prophylactic total gastrectomy is well tolerated by patients and prevents the future development of gastric cancer.","PeriodicalId":72879,"journal":{"name":"eGastroenterology","volume":" 43","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138616658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of artificial intelligence in the diagnosis of hepatocellular carcinoma.
Pub Date : 2023-11-30 eCollection Date: 2023-09-01 DOI: 10.1136/egastro-2023-100002
Benjamin Koh, Pojsakorn Danpanichkul, Meng Wang, Darren Jun Hao Tan, Cheng Han Ng

Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths worldwide. This review explores the recent progress in the application of artificial intelligence (AI) in radiological diagnosis of HCC. The Barcelona Classification of Liver Cancer criteria guides treatment decisions based on tumour characteristics and liver function indicators, but HCC often remains undetected until intermediate or advanced stages, limiting treatment options and patient outcomes. Timely and accurate diagnostic methods are crucial for enabling curative therapies and improving patient outcomes. AI, particularly deep learning and neural network models, has shown promise in the radiological detection of HCC. AI offers several advantages in HCC diagnosis, including reducing diagnostic variability, optimising data analysis and reallocating healthcare resources. By providing objective and consistent analysis of imaging data, AI can overcome the limitations of human interpretation and enhance the accuracy of HCC diagnosis. Furthermore, AI systems can assist healthcare professionals in managing the increasing workload by serving as a reliable diagnostic tool. Integration of AI with information systems enables comprehensive analysis of patient data, facilitating more informed and reliable diagnoses. The advancements in AI-based radiological diagnosis hold significant potential to improve early detection, treatment selection and patient outcomes in HCC. Further research and clinical implementation of AI models in routine practice are necessary to harness the full potential of this technology in HCC management.

{"title":"Application of artificial intelligence in the diagnosis of hepatocellular carcinoma.","authors":"Benjamin Koh, Pojsakorn Danpanichkul, Meng Wang, Darren Jun Hao Tan, Cheng Han Ng","doi":"10.1136/egastro-2023-100002","DOIUrl":"10.1136/egastro-2023-100002","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths worldwide. This review explores the recent progress in the application of artificial intelligence (AI) in radiological diagnosis of HCC. The Barcelona Classification of Liver Cancer criteria guides treatment decisions based on tumour characteristics and liver function indicators, but HCC often remains undetected until intermediate or advanced stages, limiting treatment options and patient outcomes. Timely and accurate diagnostic methods are crucial for enabling curative therapies and improving patient outcomes. AI, particularly deep learning and neural network models, has shown promise in the radiological detection of HCC. AI offers several advantages in HCC diagnosis, including reducing diagnostic variability, optimising data analysis and reallocating healthcare resources. By providing objective and consistent analysis of imaging data, AI can overcome the limitations of human interpretation and enhance the accuracy of HCC diagnosis. Furthermore, AI systems can assist healthcare professionals in managing the increasing workload by serving as a reliable diagnostic tool. Integration of AI with information systems enables comprehensive analysis of patient data, facilitating more informed and reliable diagnoses. The advancements in AI-based radiological diagnosis hold significant potential to improve early detection, treatment selection and patient outcomes in HCC. Further research and clinical implementation of AI models in routine practice are necessary to harness the full potential of this technology in HCC management.</p>","PeriodicalId":72879,"journal":{"name":"eGastroenterology","volume":"1 2","pages":"e100002"},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
eGastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1